RUZZA, Chiara
 Distribuzione geografica
Continente #
NA - Nord America 6.348
AS - Asia 3.270
EU - Europa 1.934
SA - Sud America 540
Continente sconosciuto - Info sul continente non disponibili 174
AF - Africa 76
OC - Oceania 5
Totale 12.347
Nazione #
US - Stati Uniti d'America 6.185
SG - Singapore 1.236
CN - Cina 723
IT - Italia 615
VN - Vietnam 433
BR - Brasile 404
DE - Germania 238
HK - Hong Kong 234
PL - Polonia 193
BD - Bangladesh 173
GB - Regno Unito 166
FI - Finlandia 142
UA - Ucraina 135
FR - Francia 125
TR - Turchia 103
CA - Canada 91
JP - Giappone 83
RU - Federazione Russa 81
IN - India 77
SE - Svezia 69
AR - Argentina 56
ID - Indonesia 54
MX - Messico 32
NL - Olanda 31
ZA - Sudafrica 29
IQ - Iraq 25
PK - Pakistan 25
ES - Italia 22
EC - Ecuador 21
BE - Belgio 19
IE - Irlanda 19
AT - Austria 15
CZ - Repubblica Ceca 15
UZ - Uzbekistan 15
VE - Venezuela 15
LT - Lituania 14
CO - Colombia 13
AE - Emirati Arabi Uniti 11
KE - Kenya 10
MY - Malesia 10
TN - Tunisia 10
JM - Giamaica 9
PH - Filippine 9
SA - Arabia Saudita 9
PE - Perù 7
PY - Paraguay 7
UY - Uruguay 7
CH - Svizzera 6
KR - Corea 6
NP - Nepal 6
AZ - Azerbaigian 5
CL - Cile 5
CR - Costa Rica 5
DZ - Algeria 5
KZ - Kazakistan 5
MA - Marocco 5
PR - Porto Rico 5
AL - Albania 4
AU - Australia 4
BG - Bulgaria 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
EG - Egitto 4
IL - Israele 4
JO - Giordania 4
RO - Romania 4
BO - Bolivia 3
GT - Guatemala 3
IR - Iran 3
KW - Kuwait 3
NG - Nigeria 3
NI - Nicaragua 3
NO - Norvegia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BB - Barbados 2
GY - Guiana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LV - Lettonia 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
TH - Thailandia 2
ZW - Zimbabwe 2
BJ - Benin 1
BZ - Belize 1
CI - Costa d'Avorio 1
DM - Dominica 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GP - Guadalupe 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
KN - Saint Kitts e Nevis 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
Totale 12.164
Città #
Ashburn 968
Singapore 761
Fairfield 498
San Jose 496
Woodbridge 401
Santa Clara 282
Beijing 259
Houston 242
Hong Kong 222
Seattle 221
Council Bluffs 199
Cambridge 194
Warsaw 186
Ann Arbor 183
Wilmington 183
Los Angeles 167
Ferrara 166
Chandler 161
New York 156
Jacksonville 154
Ho Chi Minh City 148
Hanoi 92
Dallas 91
Munich 87
Milan 81
Tokyo 76
Helsinki 71
Shanghai 68
Lauterbourg 65
Princeton 58
Izmir 53
Bologna 47
Chicago 44
Nanjing 44
São Paulo 40
London 39
Jakarta 38
Orem 38
Toronto 37
San Diego 34
Atlanta 31
Dearborn 31
Da Nang 28
Phoenix 28
Turku 28
Boardman 27
Frankfurt am Main 25
Brooklyn 24
Buffalo 23
Denver 23
Montreal 21
Chennai 19
Mexico City 19
Brussels 18
Dublin 18
Belo Horizonte 16
Falkenstein 16
Johannesburg 16
Lappeenranta 16
Rio de Janeiro 16
Rome 16
San Francisco 16
Addison 15
Moscow 15
Nanchang 14
Stockholm 14
Tashkent 14
Guangzhou 13
Hefei 13
Manchester 13
Memphis 13
Shenyang 13
Tianjin 13
Washington 13
Assago 12
Brasília 12
Falls Church 12
Norwalk 12
Piscataway 12
The Dalles 12
Haiphong 11
Mumbai 11
Naples 11
Padova 11
Biên Hòa 10
Lahore 10
Nairobi 10
Vienna 10
Boston 9
Bremen 9
Charlotte 9
Dhaka 9
Newark 9
Poplar 9
Baghdad 8
Changsha 8
Hải Dương 8
Minneapolis 8
Nuremberg 8
Porto Alegre 8
Totale 8.246
Nome #
Preclinical effects of cannabidiol in an experimental model of migraine 287
Pharmacological and neurobiological studies on Neuropeptide S and its receptor 280
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 267
Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor 260
[D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor: structure activity and pharmacological studies 256
Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1-13)-NH2 247
Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor 242
Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. 240
Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic- versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands 240
Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt(1)]N/OFQ(1-13) 233
Modulation of the NOP receptor signaling affects resilience to acute stress 232
Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors 232
Neuropeptide S receptor ligands: a patent review (2005-2016) 222
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives 221
Pharmacological characterization of tachykinin tetrabranched derivatives 221
Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test 218
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 214
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 214
Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands 213
In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant 210
In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations 208
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 203
Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies 203
Tetrabranched Hetero-Conjugated Peptides as Bifunctional Agonists of the NOP and Mu Opioid Receptors 200
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 199
Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice 199
Structure-activity study at positions 3 and 4 of human neuropeptide S. 197
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). 195
In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1 185
Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist 184
NOP agonist action of cebranopadol counteracts its liability to promote physical dependence 184
Novel Mixed NOP/Opioid Receptor Peptide Agonists 176
Structure-Activity Relationship Studies on Oxazolo[3,4- a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent in Vivo Activity 166
Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys 165
Lack of Direct Effects of Neurotrophic Factors in an In Vitro Model of Neuroinflammation 163
Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists 158
NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine 157
In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative 148
Dopamine D1 and D2 receptors mediate neuropeptide S-induced antinociception in the mouse formalin test 148
The concise guide to pharmacology 2021/22: G protein-coupled receptors 148
Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors 146
Effects of non-peptide nociceptin/orphanin FQ receptor ligands on methylphenidate-induced hyperactivity in mice: Implications for bipolar disorders 146
NOP Ligands for the Treatment of Anxiety and Mood Disorders 141
Highly differentiated T cells link systemic and vascular inflammation in a mouse model of recurrent psoriasis 140
Activation of peripheral NOP receptors reduces periorbital mechanical allodynia evoked by CGRP in mice 138
Detailed in vitro pharmacological characterization of the clinically viable nociceptin/orphanin FQ peptide receptor antagonist BTRX-246040 138
Biased versus Partial Agonism in the Search for Safer Opioid Analgesics 135
In vitro pharmacological characterization of growth hormone secretagogue receptor ligands using the dynamic mass redistribution and calcium mobilization assays 129
Sex differences in response to NLRP3 inflammasome blockage in a mouse migraine model: A genetic and pharmacological study 127
Blockade of nociceptin/orphanin FQ signaling facilitates an active copying strategy due to acute and repeated stressful stimuli in mice 127
Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress 125
The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus 124
Identification of isoxazole-based TRPA1 inhibitors with analgesic effects in vivo 123
Activation of NOP receptor increases vulnerability to stress: role of glucocorticoids and CRF signaling 122
Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides Targeting Opioid and NOP Receptors 122
In vitro pharmacological evaluation of the novel NOP receptor partial agonist sunobinop 122
Pharmacological characterization of naloxegol: In vitro and in vivo studies 118
The concise guide to pharmacology 2019/20: G protein-coupled receptors 117
Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. 115
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors 113
Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice 113
Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test 112
null 110
null 105
Racemic synthesis and solid phase peptide synthesis application of the chimeric valine/leucine derivative 2-amino-3,3,4-trimethyl-pentanoic acid 105
Effects of Stress Exposure to Pain Perception in Pre-Clinical Studies: Focus on the Nociceptin/Orphanin FQ-NOP Receptor System 103
In vitro pharmacological characterization of standard and new lysophosphatidic acid receptor antagonists using dynamic mass redistribution assay 97
Synthesis and Pharmacological Characterization of Nociceptin/Orphanin FQ Dimeric Ligands 89
null 87
Pharmacology, physiology and genetics of the neuropeptide s system 86
Nociceptin/OrphaninFQ Receptor Modulates the Maturation of Adult-Born Neurons in the Mouse Dentate Gyrus Under Physiological Conditions and in a Chronic Stress Model 82
An Insight into Neuronal Processing of Ghrelin: Effects of a Bioactive Ghrelin Derivative on Proteolytic Pathways and Mitophagy 79
null 77
Nociceptin/orphanin FQ receptor system blockade as an innovative strategy for increasing resilience to stress 70
The concise guide to pharmacology 2017/18: Overview 62
null 42
Skin Application of Inflammasome Inhibitor MCC950 Prevents Psoriasis-like Cutaneous Manifestations and Associated Systemic Inflammation 19
Not Quite Folded: Challenges in Predicting the hNPS‐hNPSR‐Ile107 Complex With AlphaFold2 Multimer 6
Totale 12.347
Categoria #
all - tutte 57.215
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 845
Totale 58.060


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022491 0 35 28 39 37 38 27 41 24 52 35 135
2022/2023455 58 42 23 48 58 44 39 37 50 5 27 24
2023/2024427 32 47 25 14 26 78 22 39 4 21 14 105
2024/20251.682 43 43 153 73 191 177 16 73 293 169 238 213
2025/20265.597 562 274 407 619 806 348 663 331 504 548 348 187
2026/2027708 386 322 0 0 0 0 0 0 0 0 0 0
Totale 12.347